Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 204

1.

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK.

Leukemia. 2016 May 23. doi: 10.1038/leu.2016.147. [Epub ahead of print]

PMID:
27211270
2.

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.

Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar VS, Gertz MA.

Leukemia. 2016 May 23. doi: 10.1038/leu.2016.140. [Epub ahead of print]

PMID:
27211265
3.

Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.

Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ.

Cancer. 2016 May 3. doi: 10.1002/cncr.30051. [Epub ahead of print]

PMID:
27142462
4.

Total Red Blood Cell Transfusions for Chronic Hemodialysis Patients in a Single Center, 2009-2013.

Albright RC Jr, Dillon JJ, Hocum CL, Stubbs JR, Johnson PM, Hickson LJ, Williams AW, Dingli D, McCarthy JT.

Nephron. 2016 Apr 16. [Epub ahead of print]

PMID:
27081860
5.

Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.

Gonsalves WI, Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa YL, Kourelis TV, Kyle RA, Kumar SK.

Bone Marrow Transplant. 2016 Apr 11. doi: 10.1038/bmt.2016.91. [Epub ahead of print] No abstract available.

PMID:
27064687
6.

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK.

Leuk Res. 2016 May;44:32-9. doi: 10.1016/j.leukres.2016.03.003. Epub 2016 Mar 10.

PMID:
26994849
7.

Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience.

Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Kyle RA, Gonsalves WI, Dispenzieri A.

Am J Hematol. 2016 Jun;91(6):585-9. doi: 10.1002/ajh.24356. Epub 2016 Apr 13.

PMID:
26972803
8.

Clinical characteristics and outcomes in biclonal gammopathies.

Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK.

Am J Hematol. 2016 May;91(5):473-5. doi: 10.1002/ajh.24319. Epub 2016 Apr 6.

PMID:
26840395
9.

Ontogenic growth as the root of fundamental differences between childhood and adult cancer.

Werner B, Traulsen A, Dingli D.

Stem Cells. 2016 Mar;34(3):543-50. doi: 10.1002/stem.2251. Epub 2015 Dec 22.

PMID:
26689724
10.

Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.

Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A.

Leukemia. 2016 May;30(5):1079-85. doi: 10.1038/leu.2015.344. Epub 2015 Dec 16.

PMID:
26669974
11.

An unusual cause of ascites.

Jha LK, Dingli D.

Blood. 2015 Sep 24;126(13):1629. No abstract available.

PMID:
26668859
12.

The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.

Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA.

Nephrol Dial Transplant. 2015 Nov 30. pii: gfv328. [Epub ahead of print]

PMID:
26627634
13.

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.

Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV.

Blood Cancer J. 2015 Oct 23;5:e364. doi: 10.1038/bcj.2015.87.

14.

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.

Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK.

Leukemia. 2016 Mar;30(3):633-9. doi: 10.1038/leu.2015.287. Epub 2015 Oct 21.

PMID:
26487275
15.

Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions.

Werner B, Beier F, Hummel S, Balabanov S, Lassay L, Orlikowsky T, Dingli D, Brümmendorf TH, Traulsen A.

Elife. 2015 Oct 15;4. pii: e08687. doi: 10.7554/eLife.08687.

16.

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA.

Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009. Review.

PMID:
26250727
17.

Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.

Cordes S, Gertz MA, Buadi FK, Lin Y, Lacy MQ, Kapoor P, Kumar SK, McCurdy A, Dispenzieri A, Dingli D, Hayman SR, Hogan WJ, Pruthi RK.

Blood Coagul Fibrinolysis. 2016 Jan;27(1):101-8. doi: 10.1097/MBC.0000000000000367.

PMID:
26218969
18.

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK.

Am J Hematol. 2015 Nov;90(11):981-5. doi: 10.1002/ajh.24131. Epub 2015 Oct 6.

PMID:
26214732
19.

Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.

Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK.

Am J Hematol. 2015 Oct;90(10):888-91. doi: 10.1002/ajh.24107. Epub 2015 Sep 1.

PMID:
26148022
20.

Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.

Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hwa YL, Dingli D, Kapoor P, Hayman SR, Lust JA, Kyle RA, Kumar SK.

Leukemia. 2015 Oct;29(10):2033-8. doi: 10.1038/leu.2015.118. Epub 2015 May 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk